Mayfair Gold wins Ontario fast-track permitting status for Fenn-Gib as C$310m financing plans advance
Read More Pharma Industry News Will Pictor’s targeted proteomics platform gain traction after CDC’s hepatitis B shift? Pictor’s ViraScreen-Core test aligns with new CDC hepatitis B guidance. Find out how this multiplex assay could reshape antibody testing in clinical labs. byPallavi MadhirajuDecember 24, 2025